Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Preferred Stock Liabilities: 2017-2018

  • Altimmune's Preferred Stock Liabilities was N/A to $510,083 in Q2 2018 from the same period last year, while for Jun 2018 it was $510,083, marking a year-over-year change of. This contributed to the annual value of $9.3 million for FY2017, which is N/A change from last year.
  • Altimmune's Preferred Stock Liabilities amounted to $510,083 in Q2 2018, which was down 91.43% from $6.0 million recorded in Q1 2018.
  • Over the past 5 years, Altimmune's Preferred Stock Liabilities peaked at $9.3 million during Q4 2017, and registered a low of $510,083 during Q2 2018.
  • Its 2-year average for Preferred Stock Liabilities is $6.0 million, with a median of $7.1 million in 2017.